Skip to content

Exelixis EXEL AFS Securities

AFS Securities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$630.67M-7.4%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.33B+63.3%
Royalty Pharma logo
Royalty PharmaRPRX
$406.8M+85.8%
Moderna logo
ModernaMRNA
$2.25B-6.9%
Summit Therapeutics logo
Summit TherapeuticsSMMT
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's AFS securities?
Exelixis (EXEL) reported AFS securities of $649.14M in Q1 2026.
How has Exelixis's AFS securities changed year-over-year?
Exelixis's AFS securities increased by 4.8% year-over-year, from $619.44M to $649.14M.
What is the long-term trend for Exelixis's AFS securities?
Over 5 years (2020 to 2025), Exelixis's AFS securities has grown at a 13.3% compound annual growth rate (CAGR), from $321.75M to $600.43M.